Eledon Pharmaceuticals price target lowered to $20.50 from $28 at Ladenburg

Ladenburg lowered the firm’s price target on Eledon Pharmaceuticals (ELDN) to $20.50 from $28 and keeps a Buy rating on the shares. The firm says the Phase 2 BESTOW RT study completed enrollment four months early.